W. V. Kern, Management of Staphylococcus aureus bacteremia and endocarditis: Progresses and challenges, Current Opinion in Infectious Diseases, vol.23, issue.4, pp.346-58, 2010.

A. C. Kalil, T. C. Van-schooneveld, P. D. Fey, and M. E. Rupp, Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: A systematic review and meta-analysis, JAMA, vol.312, issue.15, pp.1552-64, 2014.

V. Jarlier, D. Trystram, and C. Brun-buisson, Curbing methicillin-resistant Staphylococcus aureus in 38 french hospitals through a 15-year institutional control program, Archives of Internal Medicine, vol.170, issue.6, pp.552-561, 2010.

I. Youngster, E. S. Shenoy, D. C. Hooper, and S. B. Nelson, Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting, Clinical Infectious Diseases, vol.59, issue.3, pp.369-75, 2014.

F. Valour, J. Karsenty, and A. Bouaziz, Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus
URL : https://hal.archives-ouvertes.fr/hal-01823789

, Antimicrobial Agents and Chemotherapy, vol.58, issue.2, pp.746-55, 2014.

J. Li, K. L. Echevarria, D. W. Hughes, J. A. Cadena, J. E. Bowling et al., Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus, Antimicrobial Agents and Chemotherapy, vol.58, issue.9, pp.5117-5141, 2014.

P. Loubet, C. Burdet, and W. Vindrios, Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: A narrative review, Clinical microbiology and infection, vol.24, issue.2, pp.125-157, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01597992

J. Li, K. L. Echevarria, and K. A. Traugott, Beta-lactam therapy for methicillin-susceptible Staphylococcus aureus bacteremia: A comparative review of cefazolin versus antistaphylococcal penicillins, Pharmacotherapy, vol.37, issue.3, pp.346-60, 2017.

S. Pollett, S. M. Baxi, G. W. Rutherford, S. B. Doernberg, P. Bacchetti et al., Cefazolin versus nafcillin for methicillin-sensitive Staphylococcus aureus bloodstream infection in a california tertiary medical center, Antimicrobial Agents and Chemotherapy, vol.60, issue.8, pp.4684-4693, 2016.

J. S. Mcdanel, M. C. Roghmann, and E. N. Perencevich, Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: A nationwide cohort study, Clinical Infectious Diseases, vol.65, issue.1, pp.100-106, 2017.

M. Paul, N. Zemer-wassercug, and O. Talker, Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?, Clinical Microbiology and Infection, vol.17, issue.10, pp.1581-1587, 2011.

S. Lee, P. G. Choe, and K. H. Song, Is cefazolin inferior to nafcillin for treatment of methicillinsusceptible Staphylococcus aureus bacteremia?, Antimicrobial Agents and Chemotherapy, vol.55, issue.11, pp.5122-5128, 2011.

S. N. Rao, N. J. Rhodes, and B. J. Lee, Treatment outcomes with cefazolin versus oxacillin for deepseated methicillin-susceptible Staphylococcus aureus bloodstream infections, Antimicrobial Agents and Chemotherapy, vol.59, issue.9, pp.5232-5240, 2015.

L. K. Flynt, R. M. Kenney, M. J. Zervos, and S. L. Davis, The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections, Infectious Diseases and Therapy, vol.6, issue.2, pp.225-256, 2017.

L. M. Baddour, W. R. Wilson, and A. S. Bayer, Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications. A scientific statement for healthcare professionals from the American Heart Association, Circulation, vol.132, issue.15, pp.1435-86, 2015.

G. Habib, P. Lancellotti, and M. J. Antunes, ESC guidelines for the management of infective endocarditis: The task force for the management of infective endocarditis of the European Society of Cardiology, European Heart Journal, vol.36, issue.44, pp.3075-128, 2015.

S. Tubiana, X. Duval, and A. F. , The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia, The Journal of Infection, vol.72, issue.5, pp.544-53, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01309268

R. Ruimy, L. Armand-lefevre, and A. Andremont, Short time to positivity in blood culture with clustered gram-positive cocci on direct smear examination is highly predictive of Staphylococcus aureus, American Journal of Infection Control, vol.33, issue.5, pp.304-310, 2005.

A. S. Rossney, C. M. Herra, G. I. Brennan, P. M. Morgan, O. Connell et al., Evaluation of the Xpert methicillinresistant Staphylococcus aureus (MRSA) assay using the genexpert real-time PCR platform for rapid detection of MRSA from screening specimens, Journal of Clinical Microbiology, vol.46, issue.10, pp.3285-90, 2008.

D. H. Mitchell and B. P. Howden, Diagnosis and management of Staphylococcus aureus bacteraemia, Internal Medicine Journal, vol.35, issue.2, pp.17-24, 2005.

C. G. Gemmell, D. I. Edwards, and A. P. Fraise, Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus infections in the UK, The Journal of Antimicrobial Chemotherapy, vol.57, issue.4, pp.589-608, 2006.

C. Liu, A. Bayer, and S. E. Cosgrove, Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children, Clinical Infectious Diseases, vol.52, issue.3, pp.18-55, 2011.

L. A. Mermel, M. Allon, and E. Bouza, Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America, Clinical Infectious Diseases, vol.49, issue.1, pp.1-45, 2009.

V. G. Fowler, M. K. Olsen, and G. R. Corey, Clinical identifiers of complicated Staphylococcus aureus bacteremia, Archives of Internal Medicine, vol.163, issue.17, pp.2066-72, 2003.

S. R. Evans, D. Rubin, and D. Follmann, Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR), Clinical Infectious Diseases, vol.61, issue.5, pp.800-806, 2015.

, National institutes of health, national cancer institute, vol.26, 2010.

M. J. Crobach, T. Planche, and C. Eckert, European Society of Clinical Microbiology and Infectious Diseases: Update of the diagnostic guidance document for Clostridium difficile infection, Clinical Microbiology and Infection, vol.22, pp.63-81, 2016.

C. Jernberg, S. Lofmark, C. Edlund, and J. K. Jansson, Long-term ecological impacts of antibiotic administration on the human intestinal microbiota, The ISME Journal, vol.1, issue.1, pp.56-66, 2007.

L. Dethlefsen and D. A. Relman, Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, Proceedings of the National Academy of Sciences of the United States of America, vol.108, issue.1, pp.4554-61, 2011.

K. Forslund, S. Sunagawa, and J. R. Kultima, Country-specific antibiotic use practices impact the human gut resistome, Genome Research, vol.23, issue.7, pp.1163-1172, 2013.